Phase 2 N=23 A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
Low Grade Astrocytomas
Primary: Number of Participants With Objective Response — 4; 1; 4; 0 Participants
Phase 1 N=13 INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Phase 2 N=75 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Neurofibromatosis Type 1 · Recurrent Childhood Pilocytic Astrocytoma · Recurrent Childhood Visual Pathway Glioma
Primary: Number of Patients Who Demonstrate Complete or Partial Response — 4; 4 Participants
Phase 1 N=8 Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
N/A N=1 Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
Astrocytoma, Grade III
Primary: Number of Participants Showing no Evidence of Disease Progression Six Months After Initiating Treatment With the Device. — 1 Participants
Phase 2 N=30 A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
Anaplastic Astrocytoma · Glioblastoma
Primary: Number of Participants With Progression Free Survival (PFS) at 6 Months Utilizing McDonald Criteria for Response, Progression and Relapse — 4; 2; 2 Participants
Phase 2 N=53 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Phase 2 N=65 PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Pediatric Recurrent Progressive Low-grade Gliomas · Pediatric Progressive Low-grade Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months — 67 percentage
Phase 2 N=46 Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Brain Tumors
Primary: Event-free Survival (EFS)
Phase 2 N=11 Everolimus for Children With Recurrent or Progressive Ependymoma
Recurrent Childhood Ependymoma
Primary: Objective Response Rate (Complete Response Rate and Partial Response Rate) Following Treatment With Everolimus for Children With Recurrent or Progressive Ependymomas…
Phase 2 N=25 Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
Central Nervous System Tumor, Pediatric
Primary: 2-yr Overall Survival — 0.70 probability
Phase 2 N=19 Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma
Adult Brain Tumor
Primary: Number of Participants With Objective Response — 3; 1; 5; 9 Participants
Phase 2 N=38 Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Glial Cell Tumors · Malignant Gliomas · Glioblastoma Multiforme
Primary: 1-year Event Free Survival (EFS) — 12; 24 percentage of participants — p=< 0.05
Phase 3 N=230 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
Brain and Central Nervous System Tumors
Primary: (Phase III) Overall Survival (OS) — 3.9; 3.8 years — p=0.36
Phase 2 N=55 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Brain and Central Nervous System Tumors
Primary: Proportion of Participants With Objective Response Rate (ORR) — 5 Participants
Phase 2 N=26 Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Phase 2 N=27 Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
Anaplastic Astrocytoma
Primary: Number of Participants With Objective Response — 2; 3; 6; 10 Participants
Phase 3 N=70 Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Childhood Atypical Teratoid/Rhabdoid Tumor
Primary: Event-free Survival — 0.3401; 0.4500 Estimated probability
N/A N=66 Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
Brain Tumor · Central Nervous System Tumor
Primary: Short Term Feasibility Success — 25 participants
Phase 2 N=20 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Mixed Gliomas
Primary: Number of Participants With Objective Response — 3; 0; 4; 10 Participants
Phase 2 N=60 Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
CNS Cancer · CNS BRAIN
Primary: Progession Free Survival — 85.7 % of participants without progression
Phase 2 N=47 External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
Brain Cancer
Primary: Number of Participants With High-grade Astrocytoma and Diffuse Pontine Tumors Achieving One Year Progression Free Survival. — 5; 6 Participants
Phase 2 N=12 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Visual Pathway Glioma
Primary: Number of Participants With Objective Response — 2; 2; 3; 1 Participants
Phase 2 N=58 Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival at 6 Months. — 39; 6 Participants
Phase 2 N=32 A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
Phase 2 N=23 Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
Glioma · Low-grade Glioma · Astrocytoma
Primary: Overall Response — 2; 21 participants
Phase 1 N=26 Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Phase 2 N=121 Lerapolturev in Recurrent Malignant Glioma
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
Phase 2 N=124 A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
High Grade Glioma
Primary: Event-Free Survival (EFS) as Assessed by the Central Radiology Review Committee (CRRC) — 11.79; 8.21 months — p=0.1292